These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38213955)

  • 21. Stereoselective disposition of proton pump inhibitors.
    Andersson T; Weidolf L
    Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Study of cross reactivity between proton pump inhibitors].
    Hammami S; Affes H; Ksouda K; Feki M; Sahnoun Z; Zeghal KM
    Therapie; 2013; 68(6):361-8. PubMed ID: 24356187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermatologic adverse reactions to proton-pump inhibitors: A synthetized review.
    Salloum A; Nasr D; Maalouf D
    J Cosmet Dermatol; 2021 Apr; 20(4):1073-1079. PubMed ID: 33031621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
    Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency.
    Kato K; Mizuno T; Koseki T; Ito Y; Hatano M; Takahashi K; Yamada S; Tsuboi N
    In Vivo; 2021; 35(5):2831-2840. PubMed ID: 34410975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
    Zheng RN
    World J Gastroenterol; 2009 Feb; 15(8):990-5. PubMed ID: 19248200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
    Blanco Dorado S; Maroñas Amigo O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Br J Clin Pharmacol; 2020 Aug; 86(8):1661-1666. PubMed ID: 32110830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic management of uncomplicated gastroesophageal reflux disease in france in 2005: Potential cost savings of omeprazole substitution.
    Mouly S; Charlemagne A; Lejeunne P; Fagnani F
    Curr Ther Res Clin Exp; 2009 Aug; 70(4):282-98. PubMed ID: 24683238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cross reactivity among proton pump inhibitors: does it exits?].
    Garmendia Zallo M; Sánchez Azkarate A; Kraemer Mbula R; Liarte Ruano I; Nuñez Hernandez A; Cid De Rivera C
    Allergol Immunopathol (Madr); 2004; 32(2):92-5. PubMed ID: 15087098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
    Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
    World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of lysosomal enzyme activities by proton pump inhibitors.
    Liu W; Baker SS; Trinidad J; Burlingame AL; Baker RD; Forte JG; Virtuoso LP; Egilmez NK; Zhu L
    J Gastroenterol; 2013 Dec; 48(12):1343-52. PubMed ID: 23478938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of proton pump inhibitors in children: a comprehensive review.
    Gibbons TE; Gold BD
    Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.